Chronic calcineurin inhibitor nephrotoxicity-lest we forget

Area of Science:

• Nephrology
• Transplantation Immunology
• Pharmacology

Background:

• Calcineurin inhibitors (CNIs), including cyclosporine (CsA) and tacrolimus, are essential immunosuppressants post-transplantation.
• CNI nephrotoxicity is a recognized complication, manifesting acutely and chronically.
• Kidney biopsies in CNI recipients frequently show nephrotoxicity, with chronic toxicity and hypertension being primary concerns.

Purpose of the Study:

• To evaluate the long-term impact of continuous CsA therapy on renal function and graft survival.
• To examine the pathological hallmarks of chronic CNI nephrotoxicity.
• To address the debate surrounding the clinical significance of chronic CNI nephrotoxicity and advocate for limiting CNI exposure.

Main Methods:

• Analysis of long-term randomized clinical trial data with up to 20 years of follow-up.
• Review of pathological findings in native kidney biopsies from CNI recipients.
• Discussion of multifactorial models for chronic renal allograft loss.

Main Results:

• Continuous CsA therapy demonstrated inferiority in both renal function and graft survival compared to CsA withdrawal or azathioprine/prednisolone.
• Pathological features of chronic CNI nephrotoxicity include interstitial fibrosis, arteriolar hyalinosis, and glomerular sclerosis, though often non-specific.
• A multifactorial model incorporating immune and non-immune factors is necessary for understanding chronic renal allograft loss.

Conclusions:

• Chronic CNI nephrotoxicity remains a significant clinical entity impacting long-term transplant outcomes.
• Early diagnosis and individualized therapy are essential for mitigating CNI-related kidney damage.
• Limiting CNI exposure is vital for improving renal function and graft survival in transplant recipients.